myd88,tlr

Resatorvid (TAK-242), a selective Toll-like receptor 4 (TLR4) inhibitor, binds directly to Cys747 to prevent TLR4-TIRAP interaction, thereby blocking downstream signaling. Resatorvid exhibits antitumor, anti-inflammatory, and neuroprotective activities.

Schaftoside (APIGENIN-6-GLUCOSIDE-8-ARABINOSIDE) has antioxidant and anticancer activity.

TLR1 is a cell-penetrating Toll IL-1 receptor resistance (TIR) domain BB-Loop mimic and inhibits IL-1 receptor-mediated responses.

Pepinh-MYD TFA is a MyD88 inhibitor that features domain sequences from MyD88TIR and a protein transduction sequence, allowing it to penetrate cell membranes. By disrupting MyD88-mediated TLR pathway signaling, it inhibits related immune responses. Pepinh-MYD TFA shows potential for investigating MyD88's role in viral infections.

MyD88-IN-1 is a potent MyD88 inhibitor with anti-inflammatory activity, inhibiting downstream pathways such as the NF-κB pathway of the Toll-like receptor (TLR) and interleukin-1 (IL-1) receptor family. MyD88-IN-1 may be used in the study of cancer and inflammation treatment.

TJ-M2010-5 is a MyD88 inhibitor that binds to the TIR domain to interfere with its homodimerization and suppress MyD88 signaling. TJ-M2010-5 can be used in myocardial [ischemia reperfusion] injury studies.

Pepinh-MYD, a MyD88 inhibitor, incorporates both a domain sequence from MyD88 TIR and a protein transduction sequence to facilitate cell membrane penetration. This compound disrupts MyD88-mediated TLR signaling pathways, effectively inhibiting associated immune responses. Its design is particularly useful for investigating MyD88's function in viral infections.

IMG-2005 acts as an inhibitor of the TLR signaling pathway by mimicking the Toll interleukin-1 receptor (TIR) domain of MyD88. This action prevents the homodimerization of MyD88, mitigating damage to tracheal epithelial cells and averting the onset of pulmonary immune diseases.